| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697904 | Clinical Oncology | 2016 | 7 Pages |
Abstract
Low thymidylate synthase, low ERCC1 and high thymidine phosphorylase are candidates for predictive biomarkers for first-line treatment in advanced gastric cancer by IRI-S. Further study is warranted to confirm these results in other clinical trials and cohort studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Tsuburaya, N. Sugimoto, H. Imamura, K. Nishikawa, H. Imamoto, T. Tsujinaka, T. Esaki, Y. Horita, Y. Kimura, T. Fujiya, O. Takayama, R. Oono, H. Yabusaki, M. Taguri, S. Morita, Y. Yamada, P. Tan, M. Ninomiya, M. Sasako,